Novo Nordisk CEO: Oral Semaglutide Launch In 2020, Novel Obesity Drugs Sought
Novo Nordisk's GLP-1 franchise is advancing strongly and will be reinforced later this year by the expected approval of the ground-breaking oral semaglutide diabetes therapy, said CEO Lars Fruergaard Jørgensen
You may also be interested in...
At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity in a broad population of patients with and without established CV disease.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…